Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts
Merck closed an $8 billion senior notes offering, likely to help fund its $9.2 billion Cidara Therapeutics acquisition. The company also reported new regulatory wins and raised its dividend, but faced a patent setback for subcutaneous Keytruda in Germany. Merck shares ended December 5 at $99.72, down 1.2%, and remain near the top of their 52-week range. Trading volume was above average.